Akebia Therapeutics
Cambridge
About Akebia Therapeutics
Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $442.5M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jan 2024)
- Ticker: nasdaq:AKBA
- Website: akebia.com
- Phone: (617) 871-2098
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/akebia-therapeutics-91027 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.